NOVAVAX INC (NVAX) AI Stock Summary

Snapshot

Novavax swung to profitability in FY 2025, with $1.12B in revenue (up 65% YoY) and $440M in net income, largely from licensing and milestone payments rather than product sales. Gross margin is a strong 93.7%, but free cash flow was still negative $250M and the company burned cash operationally. It holds $735M in cash against $249M in debt, giving roughly 42 months of runway at current burn.

What's Happening Right Now

• Mon 31st Aug '26 · Stock Move: Shares extended a 30% monthly gain as investors responded to the regulatory approvals ahead of the autumn vaccination campaign and broader biotech sector strength.
• Fri 28th Aug '26 · Approval: Novavax's partners secured approvals for the XFG-adapted Nuvaxovid vaccine in the US, EU, and Japan for the 2026-27 vaccination season, extending its royalty-based, asset-light model.
• Thu 27th Aug '26 · Regulatory: On Aug 27, 2026 the FDA approved updated COVID-19 vaccines targeting the XFG variant from Moderna, Novavax-Sanofi, and Pfizer-BioNTech for the 2026-27 season.
• Wed 26th Aug '26 · Price Action: Novavax stock pulled back 2.8% to $9.18 after a recent surge to six-week highs, giving back some of its prior gains.
• Thu 6th Aug '26 · Earnings: Novavax reported Q2 2026 revenue of $57M, beat estimates, and raised its full-year 2026 revenue outlook to $235-$275M, with Sanofi milestones of $125M and $75M tied to an ongoing partnership.

Ownership

Institutions hold 84.3% of shares, while insiders hold 0.7%.

Bottom Line

Novavax has shifted from a struggling vaccine maker into a licensing-driven business, with FY 2025 net income turning positive on the strength of Sanofi and Pfizer partnerships and fresh regulatory approvals for its updated COVID-19 vaccine. Despite the improved headline profit, the company still burned cash in FY 2025 and share count grew nearly 14% year over year, a real dilution cost for existing holders. The stock is trading right at its 52-week high, meaning much of this improving story already appears priced in. A reader would want to weigh the durability of partnership revenue against the risk that easy comparisons and one-time milestones fade.